JPWO2020007729A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020007729A5 JPWO2020007729A5 JP2020572684A JP2020572684A JPWO2020007729A5 JP WO2020007729 A5 JPWO2020007729 A5 JP WO2020007729A5 JP 2020572684 A JP2020572684 A JP 2020572684A JP 2020572684 A JP2020572684 A JP 2020572684A JP WO2020007729 A5 JPWO2020007729 A5 JP WO2020007729A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- salt
- formula
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 28
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 125000001153 fluoro group Chemical group F* 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 101000887427 Homo sapiens Probable G-protein coupled receptor 142 Proteins 0.000 description 2
- 102100039861 Probable G-protein coupled receptor 142 Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18181580 | 2018-07-04 | ||
| EP18181580.4 | 2018-07-04 | ||
| PCT/EP2019/067344 WO2020007729A1 (en) | 2018-07-04 | 2019-06-28 | Triazole benzamide derivatives as gpr142 agonists |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021529189A JP2021529189A (ja) | 2021-10-28 |
| JPWO2020007729A5 true JPWO2020007729A5 (https=) | 2022-06-24 |
| JP2021529189A5 JP2021529189A5 (https=) | 2022-06-24 |
| JP7391055B2 JP7391055B2 (ja) | 2023-12-04 |
Family
ID=62873186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020572684A Active JP7391055B2 (ja) | 2018-07-04 | 2019-06-28 | Ｇｐｒ１４２アゴニストとしてのトリアゾールベンズアミド誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11179371B2 (https=) |
| EP (1) | EP3817811B1 (https=) |
| JP (1) | JP7391055B2 (https=) |
| CN (1) | CN112368049B (https=) |
| WO (1) | WO2020007729A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11179371B2 (en) | 2018-07-04 | 2021-11-23 | Boehringer Ingelheim International Gmbh | Triazole benzamide derivatives as GPR142 agonists |
| WO2022188792A1 (zh) * | 2021-03-12 | 2022-09-15 | 四川科伦博泰生物医药股份有限公司 | 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005014621D1 (de) * | 2004-03-09 | 2009-07-09 | Boehringer Ingelheim Pharma | 3-ä4-heterocyclyl-1,2,3-triazol-1-ylü-n-arylbenzamide als inhibitoren der cytokinenproduktion für die behandlung von chronischen entzündlichen erkrankungen |
| US7531560B2 (en) * | 2004-11-10 | 2009-05-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Anti-cytokine heterocyclic compounds |
| EP2079728B1 (en) | 2006-10-10 | 2013-09-25 | Amgen Inc. | N-aryl pyrazole compounds for use against diabetes |
| PE20090837A1 (es) * | 2007-07-02 | 2009-07-24 | Boehringer Ingelheim Int | Nuevos compuestos quimicos |
| WO2010093849A2 (en) | 2009-02-13 | 2010-08-19 | Amgen Inc. | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions |
| WO2015120610A1 (en) | 2014-02-14 | 2015-08-20 | Eli Lilly And Company | Gpr142 agonist compound |
| KR101921202B1 (ko) * | 2014-05-22 | 2018-11-22 | 이화여자대학교 산학협력단 | 오로라 키나아제 억제 활성을 갖는 신규한 트리아졸일살리실아마이드 유도체 |
| WO2018014337A1 (en) | 2016-07-22 | 2018-01-25 | Eli Lilly And Company | 3-Chloro-N- [ (1R, 3S) -3- [5- (3, 5-dimethylimidazol-4-yl) -4H-1, 2, 4-triazol-3-yl] cyclohexyl] -N-methyl-benzamide |
| US11179371B2 (en) | 2018-07-04 | 2021-11-23 | Boehringer Ingelheim International Gmbh | Triazole benzamide derivatives as GPR142 agonists |
-
2019
- 2019-06-28 US US17/251,576 patent/US11179371B2/en active Active
- 2019-06-28 EP EP19736632.1A patent/EP3817811B1/en active Active
- 2019-06-28 JP JP2020572684A patent/JP7391055B2/ja active Active
- 2019-06-28 CN CN201980044866.3A patent/CN112368049B/zh active Active
- 2019-06-28 WO PCT/EP2019/067344 patent/WO2020007729A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022081661A5 (https=) | ||
| JP2017522376A5 (https=) | ||
| JP2020075939A5 (https=) | ||
| JP2021528488A5 (https=) | ||
| JP2001526218A5 (https=) | ||
| JP2010501584A5 (https=) | ||
| JP2021527125A5 (https=) | ||
| JP2020511536A5 (https=) | ||
| JP2006528701A5 (https=) | ||
| JP2020529994A5 (https=) | ||
| JP2011516511A5 (https=) | ||
| JP2006504738A5 (https=) | ||
| JP2019528279A5 (https=) | ||
| JP2020111571A5 (https=) | ||
| JP2005526773A5 (https=) | ||
| JP2004525178A5 (https=) | ||
| JPH1036365A5 (https=) | ||
| JP2005526138A5 (https=) | ||
| JP2021529189A5 (https=) | ||
| JP2009525970A5 (https=) | ||
| RU97109003A (ru) | Замещенные 2-нафтоилгуанидины, способ их получения и лекарственное средство на их основе | |
| JPWO2020007729A5 (https=) | ||
| JP2019534296A5 (https=) | ||
| JP2021534221A5 (https=) | ||
| JP2020511437A5 (https=) |